Fundamental Belief
Disease Education Advocacy Groups
CancerCare® is the leading national organization dedicated to providing free, professional support services including counseling, support groups, educational workshops, publications and financial assistance to anyone affected by cancer. All CancerCare services are provided by oncology social workers and world-leading cancer experts.
The Leukemia & Lymphoma
Society (LLS) is the world's
largest voluntary nonprofit
health organization dedicated
to developing better outcomes
for blood cancer patients,
sponsoring life-saving
research, providing critical
support, education, and
resources to patients and their
families.
MPN Advocacy & Education International provides educational programs, materials and resources for patients, caregivers, physicians and entire healthcare teams to improve their understanding of myelofibrosis, polycythemia vera, and essential thrombocythemia. We are dedicated to making a difference in the lives of those affected by MPNs and strive to grow awareness and advocate on behalf of the MPN community.
Founded by patients for patients, the MPN Research Foundation is a catalyst for research funding in pursuit of new treatments – and eventually a cure – for myeloproliferative neoplasms (MPNs). We are dedicated to helping you change your prognosis by serving as a valuable source of education and resources in the MPN community.
The National Organization for Rare Disorders (NORD) is the leading independent advocacy organization representing all patients and families affected by rare diseases. NORD is committed to the identification, treatment and cure of the more than 7,000 rare diseases, of which approximately 90% are still without an FDA-approved treatment or therapy. Rare diseases affect 25-30 million Americans. More than half of those affected are children.
Patient Power is the leading producer of video interviews with medical experts and inspiring patients for people affected by cancer. Patient Power provides online and in-person events, produced in association with major patient organizations, medical centers, and clinics, and has won the trust of patients worldwide, offering expert perspective on complex health issues and providing knowledge, confidence and hope.
Our Research
Myelofibrosis (MF) - '115
Status: Not Yet Recruiting
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Navtemadlin With Ruxolitinib in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib
Myelofibrosis (MF)
Status: Active, Not Recruiting
ClinicalTrials.gov: NCT04485260An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of Navtemadlin (KRT-232) Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib.
Myelofibrosis (MF) - BOREAS
Status: Active, Not Recruiting
ClinicalTrials.gov: NCT03662126Navtemadlin (KRT-232) Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)
Myelofibrosis (MF)
Status: Active, Not Recruiting
ClinicalTrials.gov: NCT04878003An Open-Label, Multicenter, Phase 2 Study Assessing the Safety and Efficacy of Navtemadlin (KRT-232) in Janus-associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Endometrial Cancer
Status: Recruiting
ClinicalTrials.gov: NCT05797831A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
Acute Myeloid Leukemia (AML)
Status: Recruiting
ClinicalTrials.gov: NCT03041688A Phase 1B Study of KRT-232 (AMG 232) in Combination With Decitabine in Acute Myeloid Leukemia.
Glioblastoma
Status: Recruiting
ClinicalTrials.gov: NCT03107780Phase 0/I Study of KRT-232 (AMG 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters.
Multiple Myeloma
Status: Recruiting
ClinicalTrials.gov: NCT03031730A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma.
Soft Tissue Sarcoma (STS)
Status: Active, Not Recruiting
ClinicalTrials.gov: NCT03217266A Phase Ib Trial of Neoadjuvant KRT-232 (AMG 232) Concurrent With Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS)